Trials / Unknown
UnknownNCT02743416
Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,868 (actual)
- Sponsor
- Karolinska University Hospital · Academic / Other
- Sex
- All
- Age
- 75 Years – 76 Years
- Healthy volunteers
- Accepted
Summary
STROKESTOP II will study if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | ECG screening (Zenicor-ECG) for atrial fibrillation | Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation. |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
- First posted
- 2016-04-19
- Last updated
- 2020-11-25
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02743416. Inclusion in this directory is not an endorsement.